Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
65.08
-3.68 (-5.35%)
May 12, 2026, 3:00 PM CST
SHA:688399 Revenue
Jiangsu Bioperfectus Technologies had revenue of 78.58M CNY in the quarter ending March 31, 2026, a decrease of -14.22%. This brings the company's revenue in the last twelve months to 326.02M, down -6.88% year-over-year. In the year 2025, Jiangsu Bioperfectus Technologies had annual revenue of 339.05M, down -3.02%.
Revenue (ttm)
326.02M
Revenue Growth
-6.88%
P/S Ratio
16.74
Revenue / Employee
550.71K
Employees
586
Market Cap
5.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 339.05M | -10.56M | -3.02% |
| Dec 31, 2024 | 349.61M | -53.57M | -13.29% |
| Dec 31, 2023 | 403.18M | -5.13B | -92.72% |
| Dec 31, 2022 | 5.53B | 2.70B | 94.95% |
| Dec 31, 2021 | 2.84B | 1.10B | 63.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wuhan Hvsen Biotechnology | 1.74B |
| Kexing Biopharm | 1.46B |
| Shenzhen Weiguang Biological Products | 1.26B |
| ChemPartner PharmaTech | 1.14B |
| Beijing Konruns Pharmaceutical | 917.99M |
| R&G PharmaStudies | 896.26M |
| Beijing Bohui Innovation Biotechnology Group | 812.78M |
| PharmaResources (Shanghai) | 691.21M |